Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations
| Brand name | PROPAFENONE HYDROCHLORIDE |
| Generic name | PROPAFENONE HYDROCHLORIDE |
| Active ingredient(s) | PROPAFENONE HYDROCHLORIDE |
| Distributed by / for | Glenmark Pharmaceuticals Inc., USA |
| NDC | 16714-826-01 |
| Full product label | Propafenone Hydrochloride Extended-Release Capsules, USP 325mg,60-count bottles, Rx Only, Mfd for: Northstar Rx LLC, Memphis, TN 38141, Mfd by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India. NDC# 16714-826-01 |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA |
| Distribution | U.S. Nationwide |
| Quantity | N/A |
| Recall initiated | 2025-03-13 |
| Report date | 2025-04-16 |
| Recall completed | — |
| Recall number | D-0352-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Mahwah NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗